AGIO רווח נקי למניה ב-12 החודשים האחרונים agios.com
This chart, where the current level is -6.27, confirms the financial resilience of Agios Pharmaceuticals (AGIO) driven by oncology royalties and liquid reserves. The rolling annual earnings per share value is based on the firm's leadership in pyruvate kinase deficiency therapy for orphan patients. Meanwhile, the moderate predictability of cash flows depends directly on the development of new drugs and market competition.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_AGIO_-_Agios-Pharmaceuticals_-_Earnings-per-share-for-the-last-four-quarters "Agios Pharmaceuticals Inc - רווח נקי למניה (EPS TTM) AGIO (תקופה 04.07.2022 - 15.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Agios Corp (AGIO)
This metric reflects the rolling annual net income per share, allowing for an assessment of business capitalization efficiency and its ability to generate real income. For Agios Pharmaceuticals (AGIO), which possesses a monopoly platform for rare disease therapy, the 12-month net income per share chart demonstrates the financial results of a lack of market alternatives and resilient demand.
